Oncolytics Biotech 2021 Cancer Research Presentation

Investor presentation showcasing onvansertib, a first-in-class oral PLK1 inhibitor for treating multiple aggressive cancers including metastatic colorectal cancer, prostate cancer, and pancreatic adenocarcinoma. The presentation highlights clinical trial data, an integrated biomarker strategy using circulating tumor DNA and cells, and the company's diversified pipeline across numerous cancer indications.